From Injections to Pills: Breaking Down the New Oral GLP-1 Data
About this episode
Show Notes:
In this episode of Docs Who Lift, the Nadolsky brothers welcome back Dr. Sean Wharton, clinical trialist and one of the leading researchers behind the next generation of oral GLP-1 medications. Together, they break down:
The OASIS-4 trial results on 25mg oral semaglutide and how it stacks up to injectable Wegovy
How orforglipron, Eli Lilly’s new small-molecule GLP-1, differs from peptide-based drugs
Why these new therapies could make weight management more accessible and affordable
The fascinating pharmacology behind “snack molecules” and small-molecule receptor agonists
Common misconceptions about bioavailability, dosing, and side effects
The potential role of oral GLP-1s for patients with mild obesity or cardiometabolic disease
Whether you’re a clinician, researcher, or patient curious about the future of obesity medicine, this conversation offers a clear look at how science is shifting toward needle-free solutions.
Oasis 1 Trial Link
Oasis 4 Trial Link
Attain 1 Trial Link
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Docs Who Lift publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Docs Who Lift
Does Metabolically Healthy Obesity Even Exist?
Docs Who Lift
Is Your Obesity Genetic? Food Noise and Bardet-Biedl Syndrome Explained
Docs Who Lift
PCOS Renamed to PMOS? Here's Why and What Changes for You
Docs Who Lift
Are Peptides the New Snake Oil? What the Actual Science Says With Barbell Medici...
Docs Who Lift